A practical reference on AEDG: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-19. Anything still debated is marked as such rather than presented as settled.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Derived from the four-residue sequence |
| Molar mass | About 390.35 g/mol | Free peptide, counter-ion not included |
| Appearance | White to off-white powder | Lyophilised solid from aqueous solution |
| Water solubility | Freely soluble | Short, polar peptide chain |
| Common synonyms | AEDG; epithalone | Catalogues use the names interchangeably |
The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.
Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.
Ultra-high-definition television (also known as Ultra HD television, Ultra HDTV, Ultra HD, UHDTV, UHD and Super Hi-Vision) today includes 4K UHD and 8K UHD, which are two digital video formats with an aspect ratio of 16:9. These were first proposed by NHK Science & Technology Research Laboratories and later defined and approved by the International Telecommunication Union (ITU). The Consumer Electronics Association announced on October 17, 2012, that "Ultra High Definition", or "Ultra HD", would be used for displays that have an aspect ratio of 16:9 or wider and at least one digital input capable of carrying and presenting native video at a minimum resolution of 3840 × 2160. In 2015, the Ultra HD Forum was created to bring together the end-to-end video production ecosystem to ensure interoperability and produce industry guidelines so that adoption of ultra-high-definition television could accelerate. From just 30 in Q3 2015, the forum published a list of up to 55 commercial services available around the world offering 4K resolution. The "UHD Alliance", an industry consortium of content creators, distributors, and hardware manufacturers, announced during a Consumer Electronics Show (CES) 2016 press conference its "Ultra HD Premium" specification, which defines the resolution, bit depth, color gamut, high dynamic range (HDR) performance required for Ultra HD (UHDTV) content and displays to carry their Ultra HD Premium logo.
Fast growing microorganisms such as bacteria and yeast have a high concentration of nucleic acid, notably RNA. Levels must be limited in the diets of monogastric animals to <50 g per day. Ingestion of purine compounds arising from RNA breakdown leads to increased plasma levels of uric acid, which can cause gout and kidney stones. Uric acid can be converted to allantoin, which is excreted in urine. Nucleic acid removal is not necessary from animal feeds but is from human foods (humans have lost parts of the uric acid catabolic pathway during their evolution). This problem can be remediated, however. One common method consists in a heat treatment which kills the cells, inactivates proteases and allows endogenous RNases to hydrolyse RNA with release of nucleotides from cell to culture broth.
9.6 Ca(NO3)2 + 6 (NH4)2HPO4 → Ca9.6(PO4)5.6(HPO4)0.4(OH)1.6 Sintering these non-stoichiometric phases forms a solid phase which is an intimate mixture of tricalcium phosphate and hydroxyapatite, termed biphasic calcium phosphate:
Sources: en.wikipedia.org
=== Chromosomes and inherited traits === In 1927, Nikolai Koltsov proposed that inherited traits would be inherited via a "giant hereditary molecule" which would be made up of "two mirror strands that would replicate in a semi-conservative fashion using each strand as a template". Max Delbrück, Nikolay Timofeev-Ressovsky, and Karl G. Zimmer published results in 1935 suggesting that chromosomes are very large molecules the structure of which can be changed by treatment with X-rays, and that by so changing their structure it was possible to change the heritable characteristics governed by those chromosomes. In 1937 William Astbury produced the first X-ray diffraction patterns from DNA. He was not able to propose the correct structure but the patterns showed that DNA had a regular structure and therefore it might be possible to deduce what this structure was. In 1943, Oswald Theodore Avery and a team of scientists discovered that traits proper to the "smooth" form of the Pneumococcus could be transferred to the "rough" form of the same bacteria merely by making the killed "smooth" (S) form available to the live "rough" (R) form. Quite unexpectedly, the living R Pneumococcus bacteria were transformed into a new strain of the S form, and the transferred S characteristics turned out to be heritable. Avery called the medium of transfer of traits the transforming principle; he identified DNA as the transforming principle, and not protein as previously thought. He essentially redid Frederick Griffith's experiment.
=== Brown pigment gallstones === An analysis of two infants suffering from cholelithiasis observed that a substantial amount of stercobilin was present in brown pigment gallstones. This study suggested that brown pigment gallstones could form spontaneously in infants suffering from bacterial infections of the biliary tract.
According to the Bureau of Transportation Statistics, Nuevo Laredo is the busiest border crossing in terms of truck crossings with over 1.7 million trucks a year, more than double than any other crossing on the Mexico–United States border. Nuevo Laredo is the fourth-busiest border crossing in terms of passenger vehicles. Patrick Corcoran of InSight Crime believes that the turf war in Nuevo Laredo will bring a huge wave of violence, but also mentioned that the circumstances have changed since the split of the Gulf Cartel and Los Zetas in early 2010. The current alliance between Guzmán's Sinaloa Cartel and the Gulf Cartel may successfully extract Los Zetas and give Guzmán the upper hand. Once the Sinaloa Cartel gets established in Nuevo Laredo, it may possibly make moves to control Reynosa and Matamoros, Tamaulipas. In 2018, InSight also stated that infighting had developed with CJNG by March 2017 which resulted in the killing of a cartel financier and the leader of the CJNG's hit squad.
Sources: en.wikipedia.org
It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.
The name derives from epithalamin, a pineal gland extract studied in the former Soviet Union. Researchers proposed that short fragments of that extract carried the biological activity of interest.
No major regulatory agency has approved it as a medicine. It is handled as a research chemical, and products sold under this name are not standardised drugs with defined clinical labelling.
It is a synthetic tetrapeptide. Its sequence was derived from research on peptide fractions of bovine pineal extract, and the intact AEDG sequence has not been demonstrated as an abundant free peptide in human tissue.